Zofenopril calcium

MedKoo Cat#: 330196 | Name: Zofenopril calcium

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Zofenopril, also known as SQ 26991, is a ACE inhibitor that protects the heart and helps reduce high blood pressure. Zofenopril appeared significantly more effective in reducing hypertension than two older antihypertensive drugs, atenolol and enalapril, and was associated with fewer adverse effects. Zofenopril is a prodrug with zofenoprilat as the active metabolite.

Chemical Structure

Zofenopril calcium

CAS#81938-43-4 (calcium)

Theoretical Analysis

MedKoo Cat#: 330196

Name: Zofenopril calcium

CAS#: 81938-43-4 (calcium)

Chemical Formula: C44H44CaN2O8S4

Exact Mass: 0.0000

Molecular Weight: 897.16

Elemental Analysis: C, 58.91; H, 4.94; Ca, 4.47; N, 3.12; O, 14.27; S, 14.29

Price and Availability

Size	Price	Availability	Quantity
25mg	USD 475.00
100mg	USD 1,350.00

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

81938-43-4 (calcium) 81872-10-8 (free form)

Synonym

Zofenopril calcium; SQ-26991; SQ26991; SQ 26991; Zoprace;

IUPAC/Chemical Name

calcium (2S,4S)-1-((S)-3-(benzoylthio)-2-methylpropanoyl)-4-(phenylthio)pyrrolidine-2-carboxylate

InChi Key

NSYUKKYYVFVMST-LETVYOFWSA-L

InChi Code

InChI=1S/2C22H23NO4S2.Ca/c2*1-15(14-28-22(27)16-8-4-2-5-9-16)20(24)23-13-18(12-19(23)21(25)26)29-17-10-6-3-7-11-17;/h2*2-11,15,18-19H,12-14H2,1H3,(H,25,26);/q;;+2/p-2/t2*15-,18+,19+;/m11./s1

SMILES Code

O=C([C@H]1N(C([C@H](C)CSC(C2=CC=CC=C2)=O)=O)C[C@@H](SC3=CC=CC=C3)C1)[O-].O=C([C@H]4N(C([C@H](C)CSC(C5=CC=CC=C5)=O)=O)C[C@@H](SC6=CC=CC=C6)C4)[O-].[Ca+2]

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 897.16 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Lotfy HM, Monir HH, Erk N, Rostom Y. Novel feature extraction approach for achieving potential spectral resolution: Green analytical application on zofenopril calcium and hydrochlorothiazide in their spectrally overlapping binary mixture. Spectrochim Acta A Mol Biomol Spectrosc. 2020 Apr 5;230:117998. doi: 10.1016/j.saa.2019.117998. Epub 2020 Jan 7. PMID: 31931351. 2: Fayed AS, Rezk MR, Marzouk HM, Abbas SS. A Capillary Zone Electrophoresis Method with Multiresponse Chemometric Optimization for the Simultaneous Determination of Zofenopril Calcium and Hydrochlorothiazide in Presence of Hydrochlorothiazide Major Impurities. J Chromatogr Sci. 2018 May 1;56(5):461-471. doi: 10.1093/chromsci/bmy014. PMID: 29554245. 3: Rezk MR, Fayed AS, Marzouk HM, Abbas SS. A Validated High-Performance Thin- Layer Chromatographic Method for the Simultaneous Determination of Zofenopril Calcium and Hydrochlorothiazide in the Presence of the Hydrochlorothiazide Impurities: Chlorothiazide and Salamide. J AOAC Int. 2018 Jul 1;101(4):1031-1041. doi: 10.5740/jaoacint.17-0095. Epub 2017 Sep 11. PMID: 28893345. 4: Lavorini F, Chellini E, Innocenti M, Campi G, Egan CG, Mogavero S, Fontana GA. A crossover randomized comparative study of zofenopril and ramipril on cough reflex and airway inflammation in healthy volunteers. Cough. 2014 Dec 24;10(1):7. doi: 10.1186/s12997-014-0007-5. PMID: 25632296; PMCID: PMC4308941. 5: Tian Y, Cao J, Luo L, Zhang Z, Ma P. Determination of zofenopril and its active metabolite in human plasma using high-performance liquid chromatography combined with a triple-quadruple tandem mass spectrometer. J Chromatogr Sci. 2015 Feb;53(2):253-62. doi: 10.1093/chromsci/bmu050. Epub 2014 Jun 16. PMID: 24935917. 6: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2007 Nov;29(9):625-55. PMID: 18193114. 7: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2004 Mar;26(2):129-61. PMID: 15071612. 8: Matarrese M, Salimbeni A, Turolla EA, Turozzi D, Moresco RM, Poma D, Magni F, Todde S, Rossetti C, Sciarrone MT, Bianchi G, Kienle MG, Fazio F. 11C-Radiosynthesis and preliminary human evaluation of the disposition of the ACE inhibitor [11C]zofenoprilat. Bioorg Med Chem. 2004 Feb 1;12(3):603-11. doi: 10.1016/j.bmc.2003.10.054. PMID: 14738971. 9: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. Methods Find Exp Clin Pharmacol. 2003 Apr;25(3):225-48. PMID: 12743628. 10: Bayés M, Rabasseda X, Prous JR. Gateways to clinical trials. March 2003. Methods Find Exp Clin Pharmacol. 2003 Mar;25(2):145-68. PMID: 12731460. 11: Marzo A, Dal Bo L, Mazzucchelli P, Monti NC, Crivelli F, Ismaili S, Giusti A, Uhr MR. Pharmacokinetic and pharmacodynamic comparative study of zofenopril and enalapril in healthy volunteers. Arzneimittelforschung. 2002;52(4):233-42. doi: 10.1055/s-0031-1299886. PMID: 12040965. 12: Dal Bo L, Mazzucchelli P, Marzo A. Assay of zofenopril and its active metabolite zofenoprilat by liquid chromatography coupled with tandem mass spectrometry. J Chromatogr B Biomed Sci Appl. 2000 Dec 1;749(2):287-94. doi: 10.1016/s0378-4347(00)00419-9. PMID: 11145066. 13: Marzo A, Dal Bo L, Mazzucchelli P, Monti NC, Tettamanti RA, Crivelli F, Uhr MR, Ismaili S, Giusti A. Pharmacokinetics and pharmacodynamics of zofenopril in healthy volunteers. Arzneimittelforschung. 1999 Dec;49(12):992-6. doi: 10.1055/s-0031-1300539. PMID: 10635443. 14: Ambrosioni E, Borghi C, Magnani B. Survival of myocardial infarction long- term evaluation (SMILE) study: rationale, design, organization, and outcome definitions. Control Clin Trials. 1994 Jun;15(3):201-10. doi: 10.1016/0197-2456(94)90057-4. PMID: 8039405. 15: Lozano R, Joseph JM, Kline BJ. Temperature, pH and agitation rate as dissolution test discriminators of zofenopril calcium tablets. J Pharm Biomed Anal. 1994 Feb;12(2):173-7. doi: 10.1016/0731-7085(94)90027-2. PMID: 8003543. 16: Ambrosioni E, Borghi C, Magnani B. Lo studio SMILE: razionale, disegno, organizzazione e definizione degli obiettivi [The SMILE study: the rationale, design, organization and definition of the objectives. Survival of Myocardial Infarction Long-term Evaluation]. Ann Ital Med Int. 1993 Oct-Dec;8(4):230-4. Italian. PMID: 8161479. 17: Borghi C, Boschi S, Ambrosioni E, Melandri G, Branzi A, Magnani B. Evidence of a partial escape of renin-angiotensin-aldosterone blockade in patients with acute myocardial infarction treated with ACE inhibitors. J Clin Pharmacol. 1993 Jan;33(1):40-5. doi: 10.1002/j.1552-4604.1993.tb03901.x. PMID: 8429112. 18: Morrison RA, Burkett DE, Arnold ME, D'Arienzo CJ, Weinstein SH. Sites of first-pass bioactivation (hydrolysis) of orally administered zofenopril calcium in dogs. Pharm Res. 1991 Mar;8(3):370-5. doi: 10.1023/a:1015853801329. PMID: 2052527. 19: Singhvi SM, Foley JE, Willard DA, Morrison RA. Disposition of zofenopril calcium in healthy subjects. J Pharm Sci. 1990 Nov;79(11):970-3. doi: 10.1002/jps.2600791105. PMID: 2292772. 20: Borghi C, Magelli C, Boschi S, Costa FV, Capelli M, Varani E, Magnani B, Ambrosioni E. Peripheral hemodynamic and humoral effects of oral zofenopril calcium (SQ. 26,991) in patients with congestive heart failure. J Clin Pharmacol. 1989 Dec;29(12):1077-82. doi: 10.1002/j.1552-4604.1989.tb03282.x. PMID: 2533220.